Zobrazeno 1 - 10
of 13
pro vyhledávání: '"William E. Strauss"'
Autor:
Iain C. Macdougall, Naomi V. Dahl, Kristine Bernard, Zhu Li, Alka Batycky, William E. Strauss
Publikováno v:
BMC Nephrology, Vol 18, Iss 1, Pp 1-10 (2017)
Abstract Background Iron deficiency anemia (IDA) is a common manifestation of chronic kidney disease (CKD), affecting most patients on hemodialysis and imposing a substantial clinical burden. Treatment with iron supplementation increases hemoglobin l
Externí odkaz:
https://doaj.org/article/51030a260d564a2aa3a333f10b4648a8
Autor:
Iain C. Macdougall, Naomi V. Dahl, Kristine Bernard, Zhu Li, Alka Batycky, William E. Strauss
Publikováno v:
BMC Nephrology, Vol 19, Iss 1, Pp 1-1 (2018)
Following publication of the original article [1], the authors reported that one of the authors’ name is spelled incorrectly. In this Erratum the incorrect and correct author name are shown. The original publication of this article has been correct
Externí odkaz:
https://doaj.org/article/3a0f5bae91374f02b2193c5dff22851f
Autor:
John A, Glaspy, Michelle Z, Lim-Watson, Michael A, Libre, Swagata S, Karkare, Nandini, Hadker, Aleksandra, Bajic-Lucas, William E, Strauss, Naomi V, Dahl
Publikováno v:
Therapeutics and Clinical Risk Management
Background Iron deficiency anemia (IDA) is a prevalent yet underdiagnosed condition with a significant impact on quality of life. Oral iron supplementation is often poorly tolerated or yields inadequate response, requiring the use of intravenous iron
Autor:
Joseph R. Carver, Ralph B. D'Agostino, Paul W. Armstrong, William E. Strauss, Robert M. Califf
Publikováno v:
Journal of the American College of Cardiology. 27(5):1007-1019
Publikováno v:
Clinical therapeutics. 21(2)
Despite abundant evidence of the benefits of lipid lowering in reducing mortality from all causes in high-risk patients with or without coronary artery disease (CAD) and the wide availability of guidelines for targeting such patients more aggressivel
Publikováno v:
Stroke. 29(6)
F ighting heart disease and stroke ” has long been the mission as well as the slogan of the American Heart Association. Today, with the dramatic and parallel breakthroughs that have advanced treatment of both diseases, our mission and slogan have n
Autor:
William E. Strauss, Martin A. Samuels
Publikováno v:
Chest. 106(5)
Publikováno v:
Journal of cardiovascular pharmacology. 23(1)
Nicorandil (nicotinamidoethyl nitrate) is a novel vasodilator. Its vasodilator properties are related both to the nicotinamide and nitrate moieties. Classic nitrates such as nitroglycerin (NTG) and isosorbide dinitrate demonstrate in vitro inhibition
Autor:
William E. Strauss
Publikováno v:
Chest. 108:885
Autor:
Alfred F. Parisi, William E. Strauss
Publikováno v:
The American Journal of Cardiology. 53:1003-1007
Twenty-nine patients symptomatic despite beta-blocker therapy were entered into a randomized, double-blind, placebo-controlled, crossover trial of lidoflazine added to propranolol. After clinically documented beta blockade was achieved, patients were